DrugMax, Inc. today reported that preliminary April and May 2006 sales were $18.4 million and $19.0 million respectively, representing an 8.2% and 11.8% increase over April and May 2005 sales of $17.0 million and $17.0 million, respectively. Combined April and May sales totaled $37.4 million, representing an increase of 10% over the combined $34.0 million sales reported in April and May last year and an increase of 11.6% over the combined $33.5 million sales reported in January and February in the first quarter of 2006. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-14-2006/0004380552&EDATE=)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Pops Diabetes Care Gets FDA Clearance for Blood Glucose Monitor
The device’s app enables users to review their blood glucose trends and share their data with healthcare professionals and family.
FDA Warns of Stroke, Artery Lining Tear Risks for Lemtrada
The agency has updated Lemtrada’s labeling prescribing information and the patient medication guide as well as the boxed warning.
